These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37288326)

  • 41. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
    Checkley LA; Kristofek L; Kile S; Bolgar W
    Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
    Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    O'Meara S; Nanda KS; Moss AC
    Inflamm Bowel Dis; 2014 Jan; 20(1):1-6. PubMed ID: 24280879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
    Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
    J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
    Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN
    Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening.
    Ben-Shatach Z; Ziv-Baran T; Fudim E; Yavzori M; Picard O; Levartovsky A; Selinger L; Weiss B; Kopylov U; Eliakim R; Ungar B
    Therap Adv Gastroenterol; 2022; 15():17562848221083395. PubMed ID: 35646158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The incidence and management of infusion reactions to infliximab: a large center experience.
    Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
    Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.
    Wasserman MJ; Weber DA; Guthrie JA; Bykerk VP; Lee P; Keystone EC
    J Rheumatol; 2004 Oct; 31(10):1912-7. PubMed ID: 15468353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.
    Huang V; Dhami N; Fedorak D; Prosser C; Shalapay C; Kroeker KI; Halloran BP; Dieleman LA; Fedorak RN
    Can J Gastroenterol Hepatol; 2015; 29(1):35-40. PubMed ID: 25706572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
    Lahdenne P; Wikström AM; Aalto K; Kolho KL
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
    Breynaert C; Ferrante M; Fidder H; Van Steen K; Noman M; Ballet V; Vermeire S; Rutgeerts P; Van Assche G
    Am J Gastroenterol; 2011 Apr; 106(4):778-85. PubMed ID: 21407184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The extra burden of infliximab infusions in inflammatory bowel disease.
    Buisson A; Seigne AL; Dʼhuart MC; Bigard MA; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2013 Oct; 19(11):2464-7. PubMed ID: 23942563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
    Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
    J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease-A Single Center Case-Control Study.
    Szymanska E; Dadalski M; Sieczkowska-Golub J; Jarzebicka D; Meglicka M; Osiecki M; Wiernicka A; Lebensztejn DM; Korczowski B; Kierkus J
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis.
    Fumery M; Tilmant M; Yzet C; Brazier F; Loreau J; Turpin J; Le Mouel JP; Goeb V; Nguyen-Khac E; Singh S; Dupas JL; Diouf M
    Dig Liver Dis; 2019 Apr; 51(4):484-488. PubMed ID: 30686715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease.
    O'Connell DM; Nachreiner J; Shu X; Terry E; Imburgia T; Vanderloo J; Lasarev MR; Bogenschutz M
    J Pediatr Gastroenterol Nutr; 2022 May; 74(5):605-609. PubMed ID: 35149648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
    Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.